An Evidence Based Case Study to Identify the Role of Bothrops Lanceolatus as a Homeopathic Anticoagulant

Dr. Nirav Ganatra, Dr. Kinjal Mehta, Dr. Hetiksha Marakna

Medical Officer, Sainath Homoeopathic Hospital, Rajkot homoeopathic Medical College, Parul University, Rajkot, Gujarat, India

ABSTRACT

In these tough times of COVID - 19 Homoeopathy has been proven as an adjuvant intervention with standard treatment prescribed according to the clinical presentation of the patient of mild to moderate categories and also as independent mode of treatment in mild cases. Here an evidence based case study is being presented of a post-covid patient which is clinically stable but haemodynamically, alterations are marked, which were brought back to normal conditions with the help of Holistic Homoeopathy.

KEYWORDS: Anticoagulant, Haemodynamics, Covid-19, D-Dimer, Homoeopathy, Ophidia Group

Journal

 IJIORD
 International Journal of Trend in Scientific Research and Development

SSN: 2456-6470

INTRODUCTION

The second wave of the COVID-19 pandemic has major devastating effect with increasing number of cases, and hospitalizations.^[1,2]Effective management to address this infection is still evolving and attempts are being made to integrate complementary and alternative interventions along with standard care.^[3]

The COVID-19 infected cases are asymptomatic or symptomatic. The symptomatic cases are classified Mild, Moderate, Severe or critical according to the presentation. ^[3] The common clinical features observed in mild COVID-19 cases include sore throat, fever, body-ache, nasal congestion, and dry cough without any shortness of breath. Some patients are also reporting diarrhea, loss of taste/smell etc. ^[4]

WHAT IS D-DIMER?

D-dimer is a fibrin degradation product that is often used to measure and assess clot formation. Amid the COVID-19 pandemic, elevated D-dimer levels have *How to cite this paper*: Dr. Nirav Ganatra | Dr. Kinjal Mehta | Dr. Hetiksha Marakna "An Evidence Based Case Study to Identify the Role of Bothrops Lanceolatus as a Homeopathic Anticoagulant" Published in

International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-1, December 2021, pp.1572-1577,



URL:

www.ijtsrd.com/papers/ijtsrd48041.pdf

Copyright © 2021 by author (s) and International Journal of Trend in Scientific Research and Development

Journal. This is an Open Access article distributed under the



terms of the Creative Commons Attribution License (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0)

been associated with disease severity and mortality trends.^[5]

HOW D-DIMER IS SYNTHESIZED IN BODY ?:-

- The liver produces several important proteins involved in the coagulation process, one of which includes fibrinogen. A single fibrinogen molecule is a symmetrical dimer that is made up of three pairs of three different polypeptide chains, which include a, b and g. ^[5]
- Each of the intertwined polypeptide chains that comprise a single fibrinogen molecule is held together by disulfide bonds. The formation of fibrin begins with the cleaving of the a and b polypeptide chains of the fibrinogen molecule, which is achieved by thrombin. This cleaving event causes the fibrin monomers to spontaneously polymerize, which results in the formation of double-stranded fibrin protofibrils.^[6]

- To strengthen a normally weak network that exists between the fibrin monomers and the protofibrils, a transglutaminase enzyme known as factor XIIa is activated.
- If an injury occurs, the fibrinolytic system will activate to limit the size of the clot. This system begins with the release of the plasminogen activator from the vascular endothelial cells to allow this molecule to bind to the fibrin surface of plasmin. Fibrin-bound plasmin will then degrade the fibrin network into several soluble fragments, of which will include the D-dimer of the (DD)E complex.^[6]

INDICATIONS OF D-DIMER:-


The presence of D-dimer in the blood plasma, which has a half-life of roughly 8 hours until kidney clearance occurs, is often used as a clinical biomarker to identify thrombotic activity and therefore diagnose conditions like pulmonary embolism (PE), deep vein thrombosis (DVT), venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC).

IMPORTANCE OF D-DIMER IN COVID-19:-

More than one-quarter of patients with COVID-19 had elevated D-dimer levels up to 4 months after diagnosis, according to study results published in *Journal of Thrombosis and Haemostasis*. Platelets after getting exposed to Covid infection triggers the release of Platelet microbial proteins, peptides, Platelet factor (PF)-4, RANTES, and fibrino peptide B. The induction of a cytokine storm, suppression of antiviral immunity and the activation of proinflammatory response is the root cause of pathogenecity both in SARS and COVID-19.

- CoV-2 differs from SARS-CoV in interferonantagonizing and inflammasome-activating properties. "Elucidating the biological mechanisms responsible for sustained D-dimer increases may be of relevance in long COVID-19 pathogenesis and has implications for clinical management of these patients," Claimed in In research study Liam Townsend, PhD candidate in the department of infectious diseases at St. James's Hospital in Dublin, and colleagues.
- "Persistent fatigue, breathlessness and reduced exercise tolerance have been reported after acute COVID-19 infection. Although immunothrombosis has been implicated in acute COVID-19 pathogenesis, the biological mechanisms underpinning long COVID-19 remain unknown." Nearly one-third (29%) of patients with increased convalescent D-dimer levels received care exclusively in the outpatient setting. Other coagulation and inflammation markers returned to normal levels among more than 90% of convalescent patients.

"Despite ongoing symptoms and elevated Ddimers, CT pulmonary angiogram screening in eight patients failed to demonstrate pulmonary embolism," the researchers wrote.^[8]



2021;doi:10.1111/jth.15267.

HOMOEOPATHIC MANAGEMENT OF D-DIMER IN COVID-19:-

- As the Important cause of Covid-19 deaths is Coagulopathies, focus is to be viewed on reducing complementary cascade activation & Proinflammatory markers in the body preventing multi organ damage. Homoeopathy the alternative system of medicine acts in the best way when prescribed according to the routine case taking, analysis evaluation and systematic Repertorization technique. But in acute severe Infectious diseases the method of systematic analysis and Repertorization may be overlooked due to the emergency care for the patient as the need of the hour. ^[9]
- In this view some of the Homeopathic remedies which are having action on Thrombosis phenomenon were searched out. There are many Homoeopathic Remedies acting on blood vessels or plasma causing or initiating coagulation cascade. As an Alternative system of Medicine to give relief to the covid -19 sufferers,

our Homoeopathic medicines can act as adjuvants where there are many failures in conventional system and still are under trials. Though many research trials are conducted showing Homoeopathic Medicines action at Nano-particulate level, and though not fully evidenced, these medicines can be used as adjuvant to Modern system of Medicine^[9]

- Following homoeopathic remedies have potential to carry out thromboembolism and coagulopathies in the organism can be used to treat high D-Dimer values in the COVID-19 patients-
 - Bothrops Lanceolatus
 - Arnica Montana
 - Lachesis
 - Vipera
 - Fluoric Acid
 - Cardus Mur
 - Aspidosperma Quebracho
 - Arsenic alb
 - Ammonium Carbonicum^[10]

CASE PRESENTATION:-PRESENTING COMPLAIN:-

A 61-years-old Male, approached with his reports and complaints of generalized weakness, muscular cramps and twitching in calf muscles and minor coughing remaining after getting recovered from COVID-19. Clinically the patient was found very much stable but his reports showed variation in his haemodynamic state.

In his reports the value of D-DIMER was highly raised even after getting recovered from COVID-19.

PAST HISTORY:-

Diseasessufferedfrom	Ageat	Duration	Medicines&treatment taken
Renal Stone	8 yrs ago	6-7 months	Allopathic treatment

FAMILY HISTORY:-

RELATION TO PATIENT	DISEASE SUFFERING FROM	ALIVE/ DEAD	CAUSE OF DEATH
Father	HTN	Dead	
Sister	Renal stone, DM	Dead	

PERSONAL HISTORY:-

- ACCOMODATION:- Good
- ECONOMIC STATUS:- Sound
- > **DIET & FOOD HABITS:-** Addiction of alcohol
- HOBBIES:- Nothing Specific
- LIFE SPACE INVESTIGATION:BIRTH & EARLY DEVELOPMENT:-
- All the milestones were achieved normally
 - BEHAVIOUR DURING CHILDHOOD:-NAD
- **EDUCATION:-** Metric pass
- > OCCUPATIONAL HISTORY:- Farmer
- MARITAL HISTORY:- Normal
- CHILDREN:- One (Male)

GENERAL SYMPTOMS

> PHYSICAL GENERALS:-

APPEARANCE:- Lean, thin person TASTE:- not specific

THIRST:- Increased, feels unsatisfied even if drinks a large amount of water STOOL:- NAD

URINE:- 3-4/0-1 : D/N

SWEAT:- Profuse

SLEEP:- sound

THERMALREACTIONS:-(HOTCONSTITUTION: can't tolerate slight warmth)

> THERAPEUTIC INTERVENTION:-

As per the description given by patient and data obtained on questioning about his past history, family history and other examination, nothing specific was found except:-

- Increased levels of D-DIMER
- Generalized weakness after acute viral infection
- Muscular cramps and twitching in calf muscles
- HOT thermal state of patient
- Remarkable thirst

> PRESCRIPTION:-

So, On the basis of discussion and referring to various homoeopathic material medica,

- **BOTHROPS LANCEOLATUS 200 SINGLE DOSE STAT ORALLY**
- SAC-LAC 4X3X4 DAYS
- WHY BOTHROPS LANCEOLATUS?:- \geq

DR. BOERICKE SAYS:-

- Its venom is most coagulating, (also *Lachesis*). We should expect to find under these remedies symptomatology of thrombosis, also the thrombotic phenomena, as hemiplegia, aphasia, inability to articulate (Linn J. Boyd).
- Nervous trembling. •
- Pulmonary congestion.
- Broken-down, haemorrhagic constitutions; septic states.
- Great lassitude and sluggishness; Weakness^[10]
- **DISTINGUISHING BETWEEN BOTHROPS** & ARNICA:-
- The Lance snake is of the family Crotolidae; found in the island of Martinique.
- Preparations.-The poison from this snake is triturated, and dilutions are made from the 6x trituration. Bothrops is marked under remedies for Aphasia and also stroke Rubrics. But how does it compete with arnica in coagulopathies is to be op BEFORE TREATMENT:differentiated.^[11]
- The differential with Arnica is an important one . for several reasons, including the fact that because we know Arnica better, we give it more frequently. [11,12]
- When the etiology (Injury) is from the outside, the remedy is more likely to be Arnica. When the etiology is an internal process the remedy is more likely to be Bothrops. At times Bothrops is indicated even in injuries where thromboembolus arises after effects of injuries.^[13]
- Though Bothrops is given under many repertories under bleeding conditions, but Bothrops is indicated especially in bleeding after intravascular clotting and thromboembolic phenomenon.
- According to a study conducted, Bothrops has got both coagulant (clotted human fibrinogen indicating presence of Thrombin like enzyme) and anticoagulant properties (Increase in Partial thromboplastin time).

- Clinical experience by Dr. Paul Herscu says that • Bothrops initiates. Thrombi Formation leads to Fullness Restlessness, Inflammation which is followed by Bleeding, Weakness and Paralysis which brings back to the segment of thrombus Formation.
- The bleeding in Bothrops is always secondary to the coagulation, so even though there is bleeding mentioned in many locations, it rarely shows up in practice. The thrombi are much more to the point. [14]

FOLLOW UP:-.

01/05/2020 - 1st follow up:-

- ▶ Remarkable decrease in levels of D-DIMER (but still elevated)
- Improvement in weakness, ameliorated upto \geq great extent
- Relief in muscular cramps and twitching
- ► Rx:-BOTHROPS LANCEOLATUS 200 SINGLE DOSE STAT ORALLY
- SAC-LAC 4 X 3 X 7 DAYS

FOLLOW UP:-

- 04/05/2020 2nd follow up:-
- Levels of D-Dimer normalized
- Weakness absent absent
- Muscular cramps and twitching almost relieved
- Rx:- SAC-LAC 4 X 3 X 7 DAYS

) 🕲 Sup			10013
KI/III	CE LABORAT	LABORATORY REPORT		
Name : Ref. By : Dr. Self Bill. Loc. :		Ses¥çe : Male → 61 Dis. 4	Yaats	Case ID : 10483225802 P1 ID : 861294 P1 Loc :
Reg Date and Time Sample Date and Time Report Date and Time	: 28-Ap-2021 11:47 28-Ap-2021 11:48 28-Ap-2021 18:12	Siample Coll. By : NSCL	Ra	oble No. : 6680566442 fist fist
TEST		ULTS UNIT BIOL BIOCHENICAL INVESTIGAT	OGICAL REF RANGE	REMARKS
	100	DIOCHENICAL INVESTIGA	liona	
	allowing D-Clines rationed	23.00 ng FBUrni, D- a salao nagan ara proposed	600	Labile parameter. Clinica conetation or repeal with fresh sample
For announcement, the A is the first transmission of progets is the second the tester of progets of the second the tester of pro- det is the tester second second second the tester with collaboration and the tester of the councement of the tester of the tester of the councement of the tester of the pro- tein decide of the pro- tein decide of the pro- tein decide of the pro- tein decide of the tester of the tester of the tester of the councement of the advector of the pro- tein decide of the tester of the councement of the advector of the pro- tein decide of the tester of the tester of the tester of the tester of the councement of the test of the tester of the councement of the tester of the tester of the tester of the councement of the tester of tes	cleving D-Direct Inference area, 107-277 spinit, particip, 208-105 spinit, spiniter, 208-105 spinit, spiniter, 208-105 spinit, Chalacvate 6, stati Pate an undoptal catentinalism an undoptal catentinalism of cost probability assessment range indexism (PC) with the tationalism (P	a value ranges are proposed. B1-655 ngml, (1 at transient, 200-041) er to Values of 3-Dimen and Fahring lar to 2000/2017/02000 Platients of finite degradation product in format ent, a result value (500 ng FEUen) and promotively. g the fahrings obtains A and B. The for- scores and generation and finite form of an format decodingly. 5-Dimen is vary in the old accountingly. 5-Dimen is vary	Logoni, Good ternester, a on to the Course of Prysite 2008 May 24 data 13 119 Jacons Konschuter of Autor congruent In Zuang deges dation is somethier marker for somethier marker for somethier and	constalion or repeat with tresh sample s: 484-4481 rg/wl. (2nt trive con logical Preparage the Patential

Neuber		pratech		
	HOC INCORA	LABORATORY REPORT		
Name Ref. By Dr. Self Bill. Lac.		Sealige : Male (8 Dis.A3	H Years	Case ID : 10400206802 Pt ID : 061254 Pt Loc :
Reg Date and Time	: 01-Way-2021 12:5	55 Sample Type - : Plasma C	tale N	colle No. 1 8983593442
Sample Date and Time Report Date and Time		 Sampe Coll, By 1: NBCL Acc. Remarks 		didi : dide
IESI	*	ESULIS UNIT NOT BIOCHEMICAL INVESTIGA	COCAL REF BANKS	R+DARKS
C. Calman		siason multitum d		Latelepsonele: Cinto
C-Cimer CL4	0	serve der contra	- 241	cartelation or repeat with fresh sample
		NICE AN A FORCES AT PROPERTY		
n it is itself i mader of prog In the second bimester of p	equiny 291-192 m/s	- 1		
ind in the third transfer of Interse will changes and		ri. 5. 18/408 agini. (Ni barwin), 282-04	Minghet (2nd timesloc) o	nt 454-4468 ng mil (Srith Innesite I
RFF: Service A. Oyar &	A Chelstowski K, et al. To	Answer Values of D-Dimers and Flatter et the 4rd 2020 2020 0102080, Publish-	per in the Course of Physic	legical Programmy the Related
intended ase:				a second of the balance
in white feature quantificative. Venue as theoretic weakeling	mero obgest ovären så	ien of lifer degradelen brodast er forna	r parts to educe al	
in conjunction with num high Internations (DAT) and pulm		saroni, a result value <900 ng Féllumi es http://www.ikelia.	aturies deep von	
Clinical # griftcence		5040 Same manage		
		reng the Main operations: A and B. The F. o D-domine and generates a solid Ratio		
d'a foir cot le plasmin, b	sover: containing D Dim	er ale famesi accordingiy. D Dinar e vo atov iliv cul-off are obtained, devo vain	ry sonshive half or for	
plineary scholen car b	e stalaeri etti Hidi Anas	fl/tr/		
Note: Di Caner values in fre lack of diluttar wifed.	pann of Edit A plasmolaw	conswerage 1961 gher over the effore	meabering range because	
ETED 7	DEAT	Find Of Repar	8 8	• J
			<i>B</i> °	· J
Neuber		MENT:- pratech	80	· IJ
Neuber	g 🕲 Suj	MENT:- pratech	80	
Neuber	g 🕲 Suj	MENT:- pratech Calls Laboratory Report Stoage Nate (61		
Neuber	g 🕲 Suj	MENT:-	1	ND : 661254
Neuber Name Ret By Dr. Sef	g (Sup	MENT:- pratech LABORATORY REPORT SCORE NOIS (81 DB.N)		€ ID : 661254 € Loc
Neuberg		MENT:- pratech LABORATORY REPORT SCORE NOIS (81 DB.N)		R. ID : 661254 R. Loc sile No : 6603598442
Neuber Ret By Dr. Self Hit Lee Reg Dele and Time Sample Dele and Time		MENT:- Dratech ABORATORY REPORT StoAge Nale (81 DB.// : D Sample Type Planta Câl Sample Coll, By (NBCL	ale Mai	N. ID : 661254 A. Lois alle No : 6600566442 Id1 :
Neuber Kene Ret By Dr. Self Hill Lee Reg Dide and Time Sample Date and Time Report Date and Time	04/14/22/14/2 04/14/22/14/2 104/14/22/14/2	MENT:- Dratech LABORATORY REPORT StoAge Nale (61 DE. A) : D Sample Type Paerts Cál S sample Coll By : NSCL 2 4cc Remains	ala Mol Ref Ref Ref	Pt. ID : 661254 M. Los Iolia No : 6900566442 Idii : Idii : Idii :
Neuber Kene Ret By Dr. Self Hill Lee Reg Dide and Time Sample Date and Time Report Date and Time	04/14/22/14/2 04/14/22/14/2 104/14/22/14/2	MENT:- Dratech LABORATORY REPORT StoAge Nale (61 DE. A) : D Sample Type Paers Cá S sample Coll By : NSCL 2 Aze Remains	ale Mai Ref Ref Data	N. ID : 661254 A. Lois alle No : 6600566442 Id1 :
Neuber Ret By Dr. Self Int Lee Reg Dirke and Time Sample Cole and Time Report Cole and Time ILS I	SHANY2221 14 2 24400y-2221 14 2 24400y-2221 14 2 24400y-2221 14 2 24400y-2221 11 2 24400y-2221 11 2	MENT:- Dratech ABORATORY REPORT StoAge Nale (81 DE.A) : Dampe Type Paera Cal Sampe Col. By (NSCL 422 Remarks Soulds UNIT DRUG	ale Mai Ref Ref Data	Pt. ID : 661254 M. Los Iolia No : 6900566442 Idii : Idii : Idii :
Neuber Ret By Dr. Self Bit Lee Reg Dele and Time Repet Dele and Time ILES I	04/14/22/14/2 04/14/22/14/2 104/14/22/14/2	MENT:- Dratech ABORATORY REPORT StoAge Nale (81 DE.A) : Dampe Type Paera Cal Sampe Col. By (NSCL 422 Remarks Soulds UNIT DRUG	ale Mai Ref Par DOCAL HET RANGE TIONS	R. ID : 661254 A. Los Sia Na : 6890599442 Id1 : : Id2 : HE/MARKS Loble parameter. Clinical contestato or repeat with
Neuberg	SHARY-2211 14 2 SHARY-2211 14 2 SHARY-	MENT:- DI Sangle Tge Paers Cal 8 Sangle Cal By Paers Cal 8 Sangle Cal By Paers Cal 9 Arc Remains SOLIS UNI BROAD EROCHEMICAL INVESTIGAT 353.30 rg FEUVel D	ale Mai Ref Par DOCAL HET RANGE TIONS	 Close Close Bio No. 1880/566442 Bio No. 1880/566444 Bio No. 1880/56644 Bio No. 1880/56644 Bio No. 1880/5664
Neuber Rate Dy Dr. Self Marker Delevant inne Sample Dale and Time Report Dale and Time Ital Del Drear Del Drear For preparer scores, the	2 2444ay-2221 14 2 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4	MENT:- DI SERVICE SCARE STATES SCARE NAME (ST DE.A) : SARE TOP TOP THE SCARE SARE COL BY : NACL SARE COL BY : NACL SARE SCARE STATES SOLIS UNI BROAD ENCOMENICAL INVESTIGAT	ale Mai Ref Par DOCAL HET RANGE TIONS	R. ID : 661254 A. Los Sia Na : 6890599442 Id1 : : Id2 : HE/MARKS Loble parameter. Clinical consistan or repeat with
Neuber Ret By Dr. Self thit Lee Reg Diele and Time Sample Dale and Time Report Dale and Time ICS1 C-Dimer Parpagnam examples	о С Тилонан 1 и но кан 1 и	MENT:- Dratech Isoage Nale (81 DE:A) : D Sange Type Plants CA 8 Sange Col. By : NSCL 0 4/2: Remains SALIS UNI BOOL BIOCHEMICAL INVESTIGAT 353.00 rg FEUYHL 0 : reseateringes as propert	ale Mai Ref Par DOCAL HET RANGE TIONS	R. ID : 661254 A. Los Sia Na : 6890599442 Id1 : : Id2 : HE/MARKS Loble parameter. Clinical consistan or repeat with
Neuber Rel Dy Dr. Self ni Lee Heg Dele and Time Sample Cale and Time Report Cale and Time ILES I	о С Тикоски соницурание соницирание соницирнов соницирнов соницирнов соницирнов соницирнов соницирнов соницирнов соницирнов	MENT:- Dratech Storage Nale (81 DS.A) : DS.A)	i i ile Mai Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref	R. D.::661254 M. Los Sin Nol.: 8880358442 MI:: H2:: H2:: <t< td=""></t<>
Neuber Ret By Dr. Self Ret By Dr. Self Ret Dy Dr. Self Reg Dele and Time Sample Dele and Time Report Dele and Time Report Dele and Time Collinear Delinear D	2 444 ку-2021 14 2 2 444 ку-2021 14 2 2 444 ку-2021 14 2 2 444 ку-2021 14 2 2 444 ку-2021 14 2 1 44 ку-2021 14 14 14 14 14 14 14 14 14 14 14 14 14	MENT:- Dratech Stats LABORATORY REPORT Storage Nale (81 DE. A) : D Sample Opt Phone Cal Storage Nale (81 DE. A) : D Sample Cal By (NSCL 0 Acc Remarks SOLIS UNI BOOK BIOCHEMICAL INVESTIGAT 353.30 rg FEUML 0 - res solveringes as populat	I I IIII IIIIIIIIIIIIIIIIIIIIIIIIIIIII	R. D.::661254 K. Loc Ide No.: 650256442 Idi::: REXAMPLE: REXAMPLE: Lable parameter. Clinical considuent or repeat with thesh cample 4014420 rapid. (Coldimented or parameter in Taketa)
Kame Ref. By .: Dr. Self Bit Loo Eng Dale and Time Sample Dale and Time Report Dale and Time ILS I D-Dimen For prepare womer, the Interface image of prep or in the bit mode of prep or in the time medic of p and of the time medic of p and of the time medic of p pref - Stembla A. Kye M Instantio Schedel Rish Kas Instantion A. Kye M	Сонтина Сонта и полновите Сонта и полновите Сон	MENT:- Dratech Status LABORATORY REPORT Scoage Nale (81 DE.A) : DE.A) : DE.A	I Maria Ref. Maria Ref. Ref. Ref. DGCAL HET HARNES TOTAL S000 Logical Conditionality, and Intelline Consect Physicia 2020 Hey St. Accel: 011657	R. D.::661254 K. Loc Ide No.: 650256442 Idi::: REXAMPLE: REXAMPLE: Lable parameter. Clinical considuent or repeat with thesh cample 4014420 rapid. (Coldimented or parameter in Taketa)
Neuberg	<u>саничан</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u> <u>санича</u>	MENT:- Dratech Status LABORATORY REPORT Scoage Nale (81 DS.A) : DS.A) (81 DS.A) (81 D	Even Continues of the C	R. D.::661254 K. Loc Ide No.: 650256442 Idi::: REXAMPLE: REXAMPLE: Lable parameter. Clinical considuent or repeat with thesh cample 4014420 rapid. (Coldimented or parameter in Taketa)
Neuber Ret By Dr. Self Ret By Dr. Self Ret Dy Dr. Self Ret Dela and Time Sample Dela and Time Report Del	Основной с на траници	MENT:- Dratech Status LABORATORY REPORT Scokp: Nale (81 DE.A) : DE.A) : DE.A	Even Continues of the C	R. D.::661254 K. Loc Ide No.: 650256442 Idi::: REXAMPLE: REXAMPLE: Lable parameter. Clinical considuent or repeat with thesh cample 4014420 rapid. (Coldimented or parameter in Taketa)
Neuber Ret By Dr. Set Hit Lee Reg Die and Time Reg Die and Time Report Date and Report Report Sector With Report Report Date Report Report Report Date Report Report Report Date Report Report Report Date Report Report Report Report Report Report Report Report Report Report Report Report Report Report Report Report Rep	Основности у на обла у политичение и политичение Основности у политичение	MENT:- Dratech Destass LABORATORY REPORT Scokge Nale (81 DE: A) : DE: A) :	I I I I I I I I I I I I I I I I I I I	R. D.::661254 K. Loc Ide No.: 650256442 Idi::: REXAMPLE: REXAMPLE: Lable parameter. Clinical considuent or repeat with thesh cample 4014420 rapid. (Coldimented or parameter in Taketa)
Neuber Ret By Dr. Self Hill Lee Reg Dele and Time Report Date		MENT:- Dratech Status LABORATORY REPORT ScoAge Nale (81 DS.AJ : DS.AJ : DS.AJ : DS.AJ : Source Col. 59 : NSCL 242. Remains SOLIS UNI PROC EICCHENICAL INVESTIGAT BIOCHENICAL INVESTIGAT 303.09 og FEUNIL D : nor solder miger ate propertie 197-7030 sylve (14 threader), 202-307 werea folger at 2020/2020-92000. Publice on at 2020/2020/20200. Publice mind for 2020/2020/20200. Publice mind for at 2020/2020/2020/20200. Publice mind for at 2020/2020/2020/20200. Publice mind for at 2020/2020/2020/20200. Publice mind for at 2020/2020/2020/2020/2020/2020/2020/202	In the Advisor of Advi	R. D.::661254 K. Loc Ide No.: 650256442 Idi::: REXAMPLE: REXAMPLE: Lable parameter. Clinical considuent or repeat with thesh cample 4014420 rapid. (Coldimented or parameter in Taketa)
Neuber Rate Dy Dr. Self Marker Ret By Dr. Self Marker Reg Dyle and Ime Sample Date and Time Reg Dyle and Time Reg Dyle and Time Dubrer Dubrer Reg Dyle and Time Reg Dyle and		MENT:- Dratech Stats LABORATORY REPORT SCORP Nale (ST DE.N : DE.N : DE.	In the Adult Ref Ref Ref Ref Ref Ref Control Continuence (Physical Statistics) Statistics Statistic	R. D.::661254 K. Loc Ide No.: 650256442 Idi::: REXAMPLE: REXAMPLE: Lable parameter. Clinical considuent or repeat with thesh cample 4044420 rapid. (Coldimented or parameter in Taketa)
Neuber Ret By Dr. Self thit Lee Ret By Dr. Self thit Lee Reg Diele and Time Sample Dale and Time Report Dale and Time (Colored Colored Colored Resolution of the Self to Management Administry (Colored Resolution) (Colore	Основности и полновите и	MENT:- Dratech Status LABORATORY REPORT Score Nale (81 DE.A) : Score Nale (81 DE.A) : Score Nale (81 DE.A) : Score Nale (81 Score Nale (81 Sco	I I I I I I I I I I I I I I I I I I I	R. D.::661254 K. Loc Ide No.: 650256442 Idi::: REXAMPLE: REXAMPLE: Lable parameter. Clinical considuent or repeat with thesh cample 4044420 rapid. (Coldimented or parameter in Taketa)
Neuber Ret By Dr. Self thit Lee Ret By Dr. Self thit Lee Reg Diele and Time Sample Dale and Time Report Dale and Time (Colored Colored Colored Resolution of the Self to Management Administry (Colored Resolution) (Colore	Основности и полновите и	MENT:- Dratech Scarpe State (21 Scarpe Nale (21 DE.A) : Sample Type Paers Cal Sample Col. By : NSCL (24, Camaria SULIS UNI SCA EIOCHENICAL INVESTIGAT 353.00 og FEUNEL D State State (164 Heredon, 202-30) mere states mages ass proposed (175-333 av) (164 Heredon, 202-30) mere states mages ass proposed (175-333 av) (164 Heredon, 202-30) mere states mages ass proposed (175-333 av) (164 Heredon, 202-30) mere states mages ass proposed (175-333 av) (164 Heredon, 202-30) mere states and operating to Dama of mere states and operating to Dama of and the states of the states of the states of the formation and operating to Dama of the Decents and operating to Dama of the states of the st	I I I I I I I I I I I I I I I I I I I	R. D.::661254 K. Loc Ide No.: 650256442 Idi::: REXAMPLE: REXAMPLE: Lable parameter. Clinical considuent or repeat with thesh cample 4044420 rapid. (Coldimented or parameter in Taketa)
Name Dr. State of the second s	Основности и полновите и	MENT:- Dratech Status LABORATORY REPORT Score Nale (81 DE.A) : Score Nale (81 DE.A) : Score Nale (81 DE.A) : Score Nale (81 Score Nale (81 Sco	I I I I I I I I I I I I I I I I I I I	R. D.::661254 K. Loc Ide No.: 650256442 Idi::: REXAMPLE: REXAMPLE: Lable parameter. Clinical considuent or repeat with thesh cample 4044420 rapid. (Coldimented or parameter in Taketa)

DISCUSSION:-

In Indian scenario, CCRH had so far undertaken clinical trials in Dengue and Acute Encephalitis syndrome/JE with Homoeopathy as an add-on to usual care in tertian care setups. In Dengue Hemorrhagic fever, add on Homoeopathy could bring early improvement in platelet count and decrease in hospital stay by 2 days. Similarly, in Acute Encephalitis Syndrome/Japanese Encephalitis homeopathy as an adjuvant to the Institutional Management protocol could decrease death rate by 15% in comparison to those who received only Institutional Management protocol. In both the studies, adverse effect was not observed. Keeping in view the clinical success in above mentioned severe viral diseases, Homoeopathy as an adjuvant to the usual care may be tried in COVID-19 patients. Thus, homeopathy can play significant therapeutic roles.

Covid-19 presenting as Acute viral pneumonia causes thrombotic complications leading to Respiratory failure and ultimately multi system dysfunction. The COVID-19- associated coagulopathy (CAC) are distinct from those seen with bacterial Sepsis-Induced Coagulopathy (SIC) and disseminated intravascular coagulation (DIC). The CAC usually shows increased D-dimer and fibrinogen levels with minimal abnormalities in Prothrombin time and platelet count.

to prevent Coagulation is the main cause complications in covid19. In pulmonary complications Hypoxia leads to thrombus and in turn Thrombosis leads to hypoxia. The complication of coagulation leads to further damage further to multi organ failure. In coagulation resulting from Covid 19, D-Dimers are of diagnostic value which predicts the arc severity of Coagulation and assess the prognosis of diseases. Homoeopathic remedies though act well when selected on individualisation basis, in some acute emergency setups, specific remedies need to be given as the need of the hour.

REFERENCES:-

- [1] Interactive web-based dashboard at the coronavirus Resource center at Johns Hopkins University. https://coronavirus.jhu.edu/map.htm 1 [cited February 20, 2021]
- [2] Mathie R.T., Lloyd S.M., Legg L.A., Clausen J., Moss S., Davidson J.R. Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis. *Syst. Rev.* 2014; 3:142. doi: 10.1186/2046-4053-3-142.
- [3] Weiermayer P., Frass M., Peinbauer T., Ellinger L. Evidence-based homeopathy and veterinary homeopathy, and its potential to help overcome the anti-microbial resistance problem - an overview. *Schweiz. Arch. Tierheilkd.* 2020; 162:597–615.
- [4] Jacobs J. Homeopathic prevention and management of epidemic diseases. *Homeopathy*. 2018; 107:157–160.

- [5] Frass M., Linkesch M., Banyai S., Resch G., Dielacher C., Löbl T. Adjunctive homeopathic treatment in patients with severe sepsis: a randomized, double-blind, placebo-controlled trial in an intensive care unit. *Homeopathy*. 2005; 94:75–80.
- [6] Conde Diez S., Viejo Casas A., Garcia Rivero J.L., Lopez Caro J.C., Ortiz Portal F., Diaz Saez G. Impact of a homeopathic medication on upper respiratory tract infections in COPD patients: results of an observational, prospective study (EPOXILO) *Respir. Med.* 2019; 146:96–105.
- [7] Prajapati S., Sharma M., Kumar A., Gupta P., Narasimha Kumar G.V. An update on novel COVID-19 pandemic: a battle between humans and virus. *Eur. Rev. Med. Pharmacol. Sci.* 2020; 24:5819–5829.
- [8] Chakraborty P.S., Lamba C.D., Nayak D., John M.D., Sarkar D.B., Poddar A. Effect of individualized homoeopathic treatment in influenza like illness: a multicenter, single blind, randomized, placebo-controlled study. *IJRH*. 2013; 7:22–30.

1927. Pocket Manual of Homoeopathic Materia Medica Comprising the Characteristic and Guiding Symptoms of All Remedies.

- [12] Sabine D Klein, Ursula Wolf. Comparison of homeopathic globules prepared from high and ultra-high dilutions of various starting materials by ultraviolet light spectroscopy. Complementary Therapies in Medicine 24: 111-117, 2016
- [13] Dawre MS, Suresh Baburaj D, Rajan S (1987) Nomenclatural changes in Indian homeopathic medicinal plants. J Econ Taxon Bot 11: 217-223.
- [14] Suresh Baburaj D, Nain SS (1992) Further nomenclatural; changes in Indian Homoeopathic Medicinal Plants. Ancient Science of Life 11(4): 118-125. 4. Suresh Baburaj D, Rajan S, Sethuraman M (1992) Additional to the checklist of homoeopathic medicinal plants of India. CCRH quarterly Bulletin 14: 1-2.
- influenza like illness: a multicenter, single blind, randomized, placebo-controlled study. *IJRH*. 2013; 7:22–30.
 [9] Basu N., Das B.C., Tandon S. Interim management of COVID-19 by repurposed homeopathic medicines. *Homeopathy*. 2020; 109:182–183.
 [15] Clarke JH (1982) Dictionary of Practical Materia Medica. B. Jain Publishing Co, New Delhi. 21. Allen Timothy F (1982) The Encyclopedic of Pure Materia Medica. B. Jain Publishers; New Delhi.
 [16] Homoeopathic Pharmacopoeia of India. Controller of Publication, New Delhi. (1971; 1:
- [10] Hahnemann S. sixth ed. B. Jain Publishers Ltd.;
 New Delhi: 1994. Organon of Medicine.
 1974; 2: 1978; 3: 1984; 4. 1987; 5. 1990; 6.
 1999; 7. 2000; 8. 2006. 9: 2013; 10).
- [11] Boericke W W. ninth ed. Boericke and Runyon, Boericke and Tafel, Inc.; Philadelphia, PA: